关于上市制药企业商誉减值问题探讨——以B公司为例

Discussion on the Impairment of Goodwill of Listed Pharmaceutical Enterprises —Taking Company B as an Example

摘要: 随着我国经济体制的日益完善、市场竞争日趋激烈，很多企业都会选择通过并购方式进行扩张，但是随之而来的问题是对并购中被并方的估值虚高，进而形成高额的“商誉泡沫”，为上市公司的发展带来了极大的消极影响。自2023年A股上市公司披露年度财务报告数据以来，有14家上市公司计提商誉减值损失超过10亿元，其中仅有B公司1家制药企业，其他大多数是工业制造业、快速消费品行业或互联网行业中的企业，所以对于为何制药企业也会计提大额商誉减值损失，这个问题是值得深思的。文章从B公司2022年年末计提大额商誉减值损失这一事件出发，探讨B公司计提商誉减值损失的成因以及后果，并提出相应的对策和建议，以提供参考。

Abstract: With the improvement of China’s economic system and the increasingly fierce market competition, many enterprises will choose to expand through M&A, but the following problem is that the valuation of the merged party in M&A is falsely high, thus forming a high “goodwill foam”, which has brought great negative impact on the development of listed companies. Since A-share listed companies disclosed their annual financial report data in 2023, 14 listed companies have accrued goodwill impairment losses of more than 1 billion yuan, of which only one pharmaceutical company is Com-pany B, and most of the others are enterprises in the industrial manufacturing industry, fast-moving consumer goods industry or the internet industry. Therefore, it is worth pondering over why pharmaceutical companies also account for large goodwill impairment losses. Starting from the event of B Company’s provision of a large amount of goodwill impairment loss at the end of 2022, this article explores the causes and consequences of B Company’s provision of goodwill impairment loss, and proposes corresponding countermeasures and suggestions to provide a reference.